000075 SSE Health Care Sector Equal Weight Index
- 6746.03
- -19.28-0.28%
Hengrui diet pills went overseas for 6 billion US dollars, and this time they are no longer making wedding gowns for others | Insight Research
Through an innovative transaction structure, Hengrui uses minimal risk to obtain the highest potential overseas returns, while providing shareholders with more stable returns.
2024 Financial Report | Insulin Low Price Competition, Gan Li Pharmaceutical's Gains and Losses
Go out to sea
Is the healthcare market recovering? Mindray Healthcare acquires control of Whitney Healthcare at 25% premium | Insight Research
In the new year, A was born, and the leading device company Mindray entered the cardiovascular field at a premium.
Pharmacovigilance disintegrates CXO, what is the market concerned about?
It was only in December that the full-year forecast was lowered. What kind of medicine does Yakumin Biotech sell in gourds?
WuXi AppTec GAAP EPS of RMB 0.94, Revenue of RMB 10.67B
“Yemao” Tongze Healthcare's revenue growth in the third quarter was close to stagnation, and net profit fell 5.58% year on year | Financial News
Tongce Medical's revenue for the first three quarters was 2.85 billion yuan, up 2.12% year on year; net profit to mother was 512 million yuan, a decrease of 0.67% year on year.
There are not enough diet pills, Pharmacom announces another 60% increase in production capacity | Insight Research
Pharmaceutical Kangde announced today that its subsidiary Hequan Pharmaceutical will increase its peptide production capacity by 60%. At present, Hequan Pharmaceutical has begun a polypeptide production capacity expansion project for two production sites in Changzhou and Taixing. After the expansion is completed, Hequan Pharmaceutical will add multiple solid phase synthesis production lines for peptides. The new production capacity is expected to be put into use in December 2023. At that time, the volume of the peptide solid phase synthesis reactor will increase from the 20,000L originally planned to 32,000L. Previously, at the production site of Pharmaceutical Ming Kangde in Changzhou, WuXiTides put into operation two 2,000L polypeptide solid-phase synthesizers in April of this year, which means WuXiti
Huahai Pharmaceutical's refinancing bets on 100 tons of COVID-19 drugs: disputes over economic benefits still exist
In the context of tightening refinancing, the rationality and necessity of refinancing for A-share companies has received widespread attention from the market. Recently, Huahai Pharmaceutical (600521.SH) updated the refinancing inquiry response materials. Among them, the issue of the rationality of estimating the economic benefits of the production expansion plan attracted the attention of the regulatory authorities. According to the application materials, Huahai Pharmaceutical plans to raise 1,560 billion yuan to invest in the construction of “digital intelligent manufacturing of formulations”, “multi-functional production platform for specialty APIs such as antiviruses” projects, and supplementary liquidity. Among them, the “Multifunctional Production Platform for Antiviral and Other Special APIs” project involves “an annual output of 100 tons
Shanghai Fosun Pharmaceutical Reports 1H Results
WuXi AppTec Reports Q2 Results
2023 Interim Report | When CT Is No Longer a “Amulet”: What is Lianying Healthcare's MR Growth Space
Also watch This Morning
2023 Interim Report | Aibo Medical is increasing optometry and evasion and wants to launch the GDR to hit overseas markets?
Lustful and honest
It soared by 120 billion US dollars overnight! Eli Lilly vs. Novo Nordisk, the battle for diet pills begins
It is only a matter of time before K drugs become the next generation medicine king. It is only a matter of time before they become the magic medicine for weight loss.
Yao Ming Kant “Cheer” on the Magic Medicine Express for Weight Loss | Insightful Research
CXO may not be as pessimistic as market expectations. On July 31, at a time when the entire pharmaceutical sector was being drastically adjusted, the CXO sector bucked the trend and rose throughout the day due to Kanglong Chemical's performance forecast. On the evening of the same day, Yao Ming Kangde released its 2023 semi-annual report, which seemed to give the CXO industry a little more confidence. CXO's leading performance was strong. Excluding COVID-19, 2023H1 is still growing fast. Pharmacomingkang's revenue was 18.871 billion yuan, up 6.3% year on year, excluding COVID-19 commercialization projects, up 27.9% year on year; net profit for the first half of the year was 5.313 billion yuan, up 14.6% year on year; adjusted N in the first half of the year
WuXi AppTec GAAP EPS of $1.07, Revenue of $9.91B Beats by $8.57B
Zhaoyan's new drug to “hoard monkeys roll over” has come to a standstill
The fried monkey rolled over. Recently, the 2023 semi-annual report of Zhaoyan New Drug (603127.SH) predicted a sharp decline in net profit. According to the performance forecast, the net profit of Zhaoyan New Drug in the first half of 2023 is expected to be 73 million yuan to 110 million yuan, with a year-on-year decline range of 70.40% to 80.40%. Excluding the net profit of 188 million yuan in the first quarter of 2023, Zhaoyan New Pharmaceutical already lost money in the second quarter, only about -115 million yuan to -078 million yuan. However, at the same time, there was no sharp decline in revenue from Zhaoyan New Pharmaceuticals. In the first half of 2023
Shanghai Pharmaceuticals Holding Co., Ltd Goes Ex Dividend on Monday
Nvidia is leaving AI pharmaceuticals, are CXO companies expected to take off?
Performance implementation pending examination
Ardelyx Announces Acceptance Of New Drug Application For Tenapanor For Hyperphosphatemia In China; Triggers $2M Milestone Payment To Ardelyx Under The Terms Of The License Agreement Between Co And Shanghai Fosun Pharmaceutical Industrial Development Co.
Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, t
Aligos Therapeutics Announced Friday A Research Collaboration And Development Agreement With Xiamen Amoytop Biotech Co. Ltd. For Use Of Aligos' Oligonucleotide Platform For Treatment Of Liver Diseases
Aligos Therapeutics, Inc. (NASDAQ:ALGS, " Aligos" , the " Company" ))))), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver an